Reviewer #1:

**Scientific Quality:** Grade B (Very good)

**Language Quality:** Grade A (Priority publishing)

**Conclusion:** Accept (General priority)

**Specific Comments to Authors:** This mini-review articles give us comprehensive and well-organised information regarding gemcitabine-induced DNA damage response, and downstream signaling pathway, and the combinations of gemcitabine and targeted drugs. Thus, it will be of very interest to the readership. Thank you.

⇒ I appreciate your reputation.

Reviewer #2:

**Scientific Quality:** Grade B (Very good)

**Language Quality:** Grade B (Minor language polishing)

**Conclusion:** Major revision

**Specific Comments to Authors:** Pancreatic cancer (PC) is one of the most common malignancies of the digestive tract worldwide, with increased morbidity and mortality. This review describes the combinations of gemcitabine and targeted drugs and the varieties of targeted drugs other than gemcitabine provides a comprehensive view of therapies in pancreatic cancer. However, the whole review still needs to be organized more concisely. The article is currently a simple summary of tons of work. Several important sections that should be mentioned such as clinical research and natural product research were missing. Critical points for lots of work were not extracted and organized well.

⇒ I appreciate the improved points you point out.

The section of “COMBINATIONS OF NATURAL PRODUCTS AND ANTI-CANCER AGENTS, INCLUDING GEMCITABINE” is newly made, and this section is mentioned in ABSTRACT, Core Tip, INTRODUCTION, and CONCLUSION.

In INTRODUCTION, I described “An excellent review on effective combination therapies for pancreatic cancer was published recently[13]. This review was based mainly on the findings of preclinical and clinical studies[13].”, In reference No. 13, the findings of preclinical and clinical studies are described well, so I focused on the findings of basic studies in this minireview.